menu
    • menu
    [{"orgOrder":0,"company":"Rui Therapeutics","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KN5001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Rui Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rui Therapeutics \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Rui Therapeutics \/ Rui Therapeutics"},{"orgOrder":0,"company":"Rui Therapeutics","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KN3601","moa":"BCMA\/CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Rui Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rui Therapeutics \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Rui Therapeutics \/ Rui Therapeutics"},{"orgOrder":0,"company":"Rui Therapeutics","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KN3601","moa":"BCMA | CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Rui Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rui Therapeutics \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Rui Therapeutics \/ Rui Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Rui Therapeutics

    Menu

    Rui Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rui Therapeutics

                            China arrow
                            Saudi International Expo
                            Not Confirmed

                            Rui Therapeutics

                            China arrow
                            Saudi International Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KN3601

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Changhai Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm...

                            Details : KN3601 is a cell & gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 24, 2025

                            Lead Product(s) : KN3601

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Changhai Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rui Therapeutics

                            China arrow
                            Saudi International Expo
                            Not Confirmed

                            Rui Therapeutics

                            China arrow
                            Saudi International Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KN3601

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : Changhai Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of R...

                            Details : KN3601 is a cell & gene therapy candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 21, 2025

                            Lead Product(s) : KN3601

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : Changhai Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rui Therapeutics

                            China arrow
                            Saudi International Expo
                            Not Confirmed

                            Rui Therapeutics

                            China arrow
                            Saudi International Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KN5001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : The First Affiliated Hospital with Nanjing Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary ...

                            Details : KN5001 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Solitary Pulmonary Nodule.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : KN5001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : The First Affiliated Hospital with Nanjing Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth